Pharsight

1. List of Mavyret drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037	ABBVIE INC	Macrocyclic proline derived HCV serine protease inhibitors	Jan, 2032 (8 years from now)
US8937150	ABBVIE INC	Anti-viral compounds	May, 2032 (9 years from now)
USRE48923	ABBVIE INC	Crystal forms	May, 2035 (12 years from now)
US9321807	ABBVIE INC	Crystal forms	Jun, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US10039754	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US9586978	ABBVIE INC	Anti-viral compounds	Nov, 2030 (7 years from now)
US10039754 (Pediatric)	ABBVIE INC	Anti-viral compounds	Dec, 2030 (7 years from now)
US10028937 (Pediatric)	ABBVIE INC	Anti-viral compounds	Dec, 2030 (7 years from now)
US9586978 (Pediatric)	ABBVIE INC	Anti-viral compounds	May, 2031 (8 years from now)
US8648037 (Pediatric)	ABBVIE INC	Macrocyclic proline derived HCV serine protease inhibitors	Jul, 2032 (9 years from now)
US8937150 (Pediatric)	ABBVIE INC	Anti-viral compounds	Nov, 2032 (9 years from now)
US10286029	ABBVIE INC	Method for treating HCV	Mar, 2034 (11 years from now)
US11484534	ABBVIE INC	Methods for treating HCV	Mar, 2034 (11 years from now)
US10286029 (Pediatric)	ABBVIE INC	Method for treating HCV	Sep, 2034 (11 years from now)
US11484534 (Pediatric)	ABBVIE INC	Methods for treating HCV	Sep, 2034 (11 years from now)
USRE48923 (Pediatric)	ABBVIE INC	Crystal forms	Nov, 2035 (12 years from now)
US9321807 (Pediatric)	ABBVIE INC	Crystal forms	Dec, 2035 (12 years from now)
US11246866	ABBVIE INC	Solid pharmaceutical compositions for treating HCV	Jun, 2036 (13 years from now)
US11246866 (Pediatric)	ABBVIE INC	Solid pharmaceutical compositions for treating HCV	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 3, 2022
New Patient Population (NPP)	Apr 30, 2022
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
New Dosing Schedule (D)	Sep 26, 2022
M	Apr 10, 2023
Pediatric Exclusivity (PED)	Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG;40MG	TABLET;ORAL	Prescription

2. List of Oriahnn (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2024 (1 year, 5 months from now)
US7056927	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Sep, 2024 (1 year, 7 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11459305	ABBVIE INC	Processes for the preparation of uracil derivatives	Nov, 2028 (5 years from now)
US11045470	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)
US10881659	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023
New Product (NP)	May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	CAPSULE;ORAL	Prescription

3. List of Orilissa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2024 (1 year, 5 months from now)
US7056927	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Sep, 2024 (1 year, 7 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Jul, 2024 (1 year, 5 months from now)
US11344551	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)
US10537572	ABBVIE INC	Methods of administering elagolix	Sep, 2036 (13 years from now)
US10682351	ABBVIE INC	Methods of administering elagolix	Sep, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg and 200 mg	25 Jul, 2022	9		01 Sep, 2036

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Prescription

4. List of Qulipta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545	ABBVIE INC	Piperidinone carboxamide azaindane CGRP receptor antagonists	Nov, 2031 (8 years from now)
US8754096	ABBVIE INC	Piperidinone carboxamide azaindane CGRP receptor antagonists	Jul, 2032 (9 years from now)
US9850246	ABBVIE INC	Process for making CGRP receptor antagonists	Mar, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836	ABBVIE INC	Tablet formulation for CGRP active compounds	Jan, 2035 (12 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

5. List of Rinvoq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221	ABBVIE INC	Tricyclic compounds	Dec, 2030 (7 years from now)
US8962629	ABBVIE INC	Tricyclic compounds	Jan, 2031 (7 years from now)
US9951080	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10981923	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11186584	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10519164	ABBVIE INC	Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US9963459	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof	Oct, 2036 (13 years from now)
US10981924	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10344036	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10550126	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10730883	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11198697	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10597400	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11365198	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10202393	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10995095	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11512092	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 14, 2024
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
45MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

6. List of Technivie drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642538	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Sep, 2029 (6 years from now)
US8420596	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Apr, 2031 (8 years from now)
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349	ABBVIE INC	Solid pharmaceutical dosage form	Aug, 2024 (1 year, 6 months from now)
US8399015	ABBVIE INC	Solid pharmaceutical dosage form	Aug, 2024 (1 year, 6 months from now)
US8268349 (Pediatric)	ABBVIE INC	Solid pharmaceutical dosage form	Feb, 2025 (2 years from now)
US8399015 (Pediatric)	ABBVIE INC	Solid pharmaceutical dosage form	Feb, 2025 (2 years from now)
US9006387	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US9044480	ABBVIE INC	Compositions and methods for treating HCV	Apr, 2031 (8 years from now)
US8686026	ABBVIE INC	Solid compositions	Jun, 2031 (8 years from now)
US8420596 (Pediatric)	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Oct, 2031 (8 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

Strength	Dosage	Availability
12.5MG;75MG;50MG	TABLET;ORAL	Discontinued

7. List of Venclexta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546399	ABBVIE INC	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases	Jun, 2031 (8 years from now)
US10730873	ABBVIE INC	Salts and crystalline forms of an apoptosis-inducing agent	Nov, 2031 (8 years from now)
US8722657	ABBVIE INC	Salts and crystalline forms of an apoptosis-inducing agent	Jan, 2032 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982	ABBVIE INC	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases	May, 2030 (7 years from now)
US11369599	ABBVIE INC	Melt-extruded solid dispersions containing an apoptosis-inducing agent	May, 2032 (9 years from now)
US10993942	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	Sep, 2033 (10 years from now)
US11413282	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	Sep, 2033 (10 years from now)
US11110087	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	Sep, 2033 (10 years from now)
US9539251	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	Sep, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 15, 2026
New Indication (I)	May 15, 2022
M	Oct 16, 2023

Drugs and Companies using VENETOCLAX ingredient

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles followed by administration in absence of obinutuzumab; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg, 50 mg and 100 mg	13 Apr, 2020	2		29 Jan, 2032

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

8. List of Viekira Pak (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238	ABBVIE INC	Anti-infective agents and uses thereof	Dec, 2028 (5 years from now)
US8188104	ABBVIE INC	Anti-infective agents and uses thereof	May, 2029 (6 years from now)
US8642538	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Sep, 2029 (6 years from now)
US8420596	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Apr, 2031 (8 years from now)
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015	ABBVIE INC	Solid pharmaceutical dosage form	Aug, 2024 (1 year, 6 months from now)
US8268349	ABBVIE INC	Solid pharmaceutical dosage form	Aug, 2024 (1 year, 6 months from now)
US9139536	ABBVIE INC	Anti-infective agents and uses thereof	Nov, 2028 (5 years from now)
US9006387	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US9044480	ABBVIE INC	Compositions and methods for treating HCV	Apr, 2031 (8 years from now)
US8686026	ABBVIE INC	Solid compositions	Jun, 2031 (8 years from now)
US8685984	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8492386	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8466159	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8680106	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US9629841	ABBVIE INC	Formulations of pyrimidinedione derivative compounds	Oct, 2033 (10 years from now)
US10201542	ABBVIE INC	Formulations of pyrimidinedione derivative compounds	Oct, 2033 (10 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG	TABLET;ORAL	Discontinued

9. List of Viekira Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238	ABBVIE INC	Anti-infective agents and uses thereof	Sep, 2028 (5 years from now)
US8188104	ABBVIE INC	Anti-infective agents and uses thereof	May, 2029 (6 years from now)
US8642538	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Sep, 2029 (6 years from now)
US8420596	ABBVIE INC	Macrocyclic hepatitis C serine protease inhibitors	Apr, 2031 (8 years from now)
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015	ABBVIE INC	Solid pharmaceutical dosage form	Aug, 2024 (1 year, 6 months from now)
US8268349	ABBVIE INC	Solid pharmaceutical dosage form	Aug, 2024 (1 year, 6 months from now)
US9139536	ABBVIE INC	Anti-infective agents and uses thereof	Nov, 2028 (5 years from now)
US9006387	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US9044480	ABBVIE INC	Compositions and methods for treating HCV	Apr, 2031 (8 years from now)
US8686026	ABBVIE INC	Solid compositions	Jun, 2031 (8 years from now)
US10201584	ABBVIE INC	Compositions and methods for treating HCV	May, 2032 (9 years from now)
US10201541	ABBVIE INC	Compositions and methods for treating HCV	May, 2032 (9 years from now)
US8492386	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8685984	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8466159	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8680106	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US10105365	ABBVIE INC	Solid antiviral dosage forms	Jan, 2035 (11 years from now)
US9333204	ABBVIE INC	Solid antiviral dosage forms	Jan, 2035 (11 years from now)
US9744170	ABBVIE INC	Solid antiviral dosage forms	Jan, 2035 (11 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 22 July, 2016

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 200MG BASE;8.33MG;50MG;33.33MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

10. List of Vuity drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610518	ABBVIE INC	Presbyopia treatments	Apr, 2039 (16 years from now)
US11285134	ABBVIE INC	Presbyopia treatments	Apr, 2039 (16 years from now)